Morepen Laboratories Ltd
Ticker: MOREPENLAB
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
48.09
Market Cap
2635.11
Debt/Equity
0.0885
ROE %
11.604
PB
2.2200
Promoter %
35.655
Pledge %
0.000
1Y Rev Growth %
7.366
5Y Rev Growth %
16.233
NP Margin %
6.449
NP Margin 5Y Avg %
5.886
Trading Reference
1M Return %
-10.735
6M Return %
-8.208
1Y Return %
-46.136
% Away 52W High
96.403
% Away 52W Low
14.500
Daily Volume
1042469
Investment Verdict
Hold
Score 69/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 19/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Morepen Laboratories Ltd is currently trading near a key support level, with recent volume indicating accumulation. If it breaks above the resistance level at 100, there is potential for a bullish trend, while a drop below 80 could signal a bearish outlook.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
S
Stylam Industries Ltd
Stylam Industries Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised for new investors.
View details
H
Honda India Power Products Ltd
Honda India Power Products Ltd shows decent potential but faces challenges in profitability and execution risks.
View details
X
Xpro India Ltd
Xpro India Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
G
Gujarat Industries Power Company Ltd
Gujarat Industries Power Company Ltd shows potential in a critical sector, but faces challenges in growth consistency and valuation metrics.
View details
S
String Metaverse Ltd
String Metaverse Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
D
Digitide Solutions Ltd
Digitide Solutions Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
H
Hind Rectifiers Ltd
Hind Rectifiers Ltd shows potential in a growing sector but faces challenges in consistent growth and market sentiment.
View details
R
RPSG Ventures Ltd
RPSG Ventures Ltd presents a mixed outlook with several risks that could impact future performance. Caution is advised for potential investors.
View details
A
Arvind Smartspaces Ltd
Arvind Smartspaces Ltd presents a risky investment opportunity due to inconsistent growth and profitability metrics, alongside concerns in governance and market sentiment.
View details
A
AGI Infra Ltd
AGI Infra Ltd shows potential in a growing sector but faces challenges in execution and profitability consistency.
View details
R
Rossell Techsys Ltd
Rossell Techsys Ltd shows potential in a future-ready sector but faces challenges in growth consistency and valuation metrics. Caution is advised for investors.
View details
H
Hindware Home Innovation Ltd
Hindware Home Innovation Ltd shows potential in a growing sector, but faces challenges in profitability and market sentiment.
View details
S
Savita Oil Technologies Ltd
Savita Oil Technologies Ltd shows decent fundamentals but faces challenges in profitability and market competition.
View details
J
Jai Corp Ltd
Jai Corp Ltd presents a mixed outlook with several risks that may hinder growth and profitability. Caution is advised.
View details
S
Sandhar Technologies Ltd
Sandhar Technologies Ltd shows potential in a growing sector, but faces challenges in execution and profitability consistency.
View details
K
KP Green Engineering Ltd
KP Green Engineering Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Business Overview
Morepen Laboratories Ltd is a prominent Indian healthcare company specializing in the manufacturing of pharmaceutical products and diagnostic devices. Catering to both domestic and international markets, Morepen focuses on delivering quality healthcare solutions that enhance the well-being of individuals. The company is committed to innovation and sustainability, making it a trusted name in the industry. With a robust portfolio of products ranging from APIs to consumer healthcare, Morepen is well-positioned to meet the growing healthcare demands in India and beyond.
- Established leader in pharmaceuticals and diagnostics
- Wide range of quality healthcare products
- Strong commitment to innovation and sustainability
- Catering to both domestic and international markets
- Trusted brand with a focus on enhancing well-being
Investment Thesis
Morepen Laboratories Ltd stands out due to its strong promoter credibility, robust growth in digital services, and attractive valuation compared to peers. This combination positions it as a compelling investment opportunity in the healthcare sector.
- Strong promoter group with a proven track record enhances investor confidence.
- Significant growth potential in digital healthcare services aligns with market trends.
- Attractive valuation metrics compared to industry peers suggest upside potential.
- Diverse product portfolio mitigates risks and drives revenue stability.
- Strategic initiatives in R&D position the company for long-term growth.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Expansion into international markets
- Strong R&D capabilities
- Strategic partnerships with pharmacies
- Increasing online sales channels
Risks ⚠️
- Regulatory changes in pharmaceuticals
- Intense competition in the sector
- Supply chain disruptions
- Dependence on key products
- Market volatility affecting stock price
Peer Perspective
Morepen Laboratories Ltd trades at a 20% discount to peers like Cipla and Sun Pharma, primarily due to margin volatility. A sustained improvement in operational efficiency could trigger a rerating in its valuation.
Future Outlook
Morepen Laboratories Ltd is well-positioned for growth, driven by its expanding product portfolio and market reach; however, successful execution and stringent cost control will be crucial to fully realize its potential.
AI FAQs for Retail Users
- Q: What does Morepen Laboratories Ltd do?A: Morepen Laboratories Ltd is involved in manufacturing pharmaceutical products and diagnostic tools.
- Q: Is Morepen Laboratories Ltd a good investment?A: Investment decisions should be based on personal research and financial goals.
- Q: What are the main products of Morepen Laboratories Ltd?A: The company offers APIs, formulations, and diagnostic kits, among other healthcare products.
- Q: How can I buy shares of Morepen Laboratories Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: What is the company's financial performance like?A: Review the latest financial reports and market analysis for insights on performance.
📊 Stock Investment Checklist (100 Points)
Morepen Laboratories Ltd • Updated: 2025-09-17 03:54:52
-
8BusinessHighThe sector shows potential due to increasing healthcare demands, but competition is high.
-
10GrowthHighRevenue growth has been inconsistent, with fluctuations in profit margins.
-
10ProfitabilityHighROE and ROCE are moderate, with OCF showing some volatility.
-
9ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity ratios need improvement.
-
6GovernanceGoodPromoter holding is decent, but there are concerns about pledging.
-
5DriversGoodGrowth drivers exist, but execution risks are significant.
-
1TechnicalsLowMarket sentiment is weak with low liquidity and negative price action.
Final Score & Verdict
Score 48 / 100
• Risky
Morepen Laboratories Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 55/100
- Market Confidence: 65/100